DEF: DiaMedica Sets 2026 AGM, Seeks Shareholder Approval for Director Elections, Auditor, Executive Pay, and Expanded Equity Plan

DiaMedica Therapeutics Inc. announced its 2026 Annual General Meeting to vote on director elections, auditor ratification, executive compensation, and a significant increase in its equity incentive plan shares.

Summary

• The 2026 Annual General Meeting of Shareholders will be held on Wednesday, May 20, 2026, at 9:00 a.m. CDT, at the company's corporate offices in Minneapolis, Minnesota.
• Shareholders will vote on four key proposals: the election of seven directors, the ratification of Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year 2026, an advisory vote on executive compensation, and the approval of an amendment to the 2019 Omnibus Incentive Plan.
• The proposed amendment to the 2019 Omnibus Incentive Plan seeks to increase the number of shares available for issuance by an additional 3,500,000 shares, bringing the total to 10,500,000 shares, and to extend the plan's term for ten years until May 19, 2036.
• The Board of Directors unanimously recommends a vote FOR all seven director nominees and FOR approval of all other proposals.
• As of March 23, 2026, there were 53,805,628 common shares outstanding, with a quorum requiring at least 17,935,210 common shares (33 1/3%).
• Executive compensation for 2025 included a 10% base salary increase for the CEO and CFO, and the appointment of Julie Krop, M.D. as CMO with an initial annual base salary of $525,000.
• Short-term incentive payouts for 2025 were 125% of target for the CEO ($412,500), 100% for the CMO ($79,592 prorated), and 110% for the CFO ($183,920), based on 100% achievement of corporate objectives and 100-150% of individual objectives.
• The company's three-year average burn rate for equity awards (2023-2025) was approximately 5.3%, and the proposed additional shares are expected to cover awards for approximately three years.
• The overhang, representing outstanding equity awards and shares available for future grants, would increase from 15.9% to 22.4% if the plan amendment is approved.
• Significant beneficial owners as of March 23, 2026, include Trill AB (16.4%), TomEqt Private AB (15.58%), Richard Jacinto II (9.2%), and Leon G. Cooperman (6.4%).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting standard governance practices and a necessary equity plan expansion for a clinical-stage biotech, supported by strong TSR despite expected operational losses.

Positives

• The Board of Directors maintains strong corporate governance practices, including annual election of directors, a majority of independent directors, an independent Board Chairman, and four fully independent Board committees.
• Executive compensation practices emphasize 'pay for performance,' with a significant portion of executive compensation at risk and paid in equity, aligning management interests with shareholders.
• The company has a clawback policy and prohibits hedging/pledging of DiaMedica securities, reflecting sound corporate governance.
• The proposed amendment to the 2019 Omnibus Incentive Plan includes sound governance features such as no automatic share replenishment, no repricing of stock options without shareholder approval, and no discounted stock options.
• The company's Total Shareholder Return (TSR) has shown significant growth, with an initial $100 investment growing to $504 by 2025, indicating strong market performance over the past three fiscal years.
• The Audit Committee has determined that James Parsons and Daniel O'Connor qualify as audit committee financial experts, enhancing financial oversight.

Negatives

• The proposed amendment to the 2019 Omnibus Incentive Plan will increase potential dilution and overhang, with overhang rising from 15.9% to 22.4% if approved.
• The company has incurred substantial and increasing net losses over the past three fiscal years: $(19,381) million in 2023, $(24,444) million in 2024, and $(32,766) million in 2025.
• There were delinquent Section 16(a) reports filed by Julie Krop (one late Form 3, one late Form 4) and by Trill AB and Jan Stahlberg (two late Form 4s for multiple transactions) during fiscal 2025.

Risks

• The company's continuing ability to offer equity incentive awards is critical to attracting, motivating, and retaining qualified personnel in highly competitive markets, and failure to approve the plan amendment could hinder this.
• As a clinical-stage company, DiaMedica expects to continue incurring substantial losses for at least two or three more years, which is a significant financial risk.
• The registration rights agreement from the June 2024 private placement includes a liquidated damages clause, requiring the company to pay up to 10% of invested capital if it fails to keep the resale registration statement effective, subject to certain exceptions.

Future Outlook

The company expects to continue incurring substantial losses for at least two or three more years as it progresses as a clinical-stage biopharmaceutical company. The proposed increase in the equity incentive plan shares is anticipated to cover awards for approximately three years, supporting the attraction and retention of talent crucial for executing business strategy and increasing shareholder value.

Management Comments

• "Together with our Board of Directors and the management team at DiaMedica Therapeutics Inc., we are pleased to invite you to our 2026 Annual General Meeting of Shareholders."
• "The Board of Directors recommends a vote: FOR each of the seven nominees for director named in the proxy statement and FOR approval of each of the other proposals being submitted to a vote of our shareholders."
• "Voting your DiaMedica common shares is easily achieved without attending the meeting in person. Your proxy is important to ensure a quorum is present for the meeting."
• "On behalf of the Board of Directors, we thank you for your participation, investment, and support."

Industry Context

StockSavvy.ai notes that DiaMedica Therapeutics Inc.'s focus on securing shareholder approval for its equity incentive plan is a common strategy in the highly competitive biopharmaceutical industry. Companies in this sector heavily rely on equity-based compensation to attract and retain top scientific, clinical, and executive talent, especially given the long development cycles and significant capital requirements. The company's increasing net losses are typical for a clinical-stage biotech, where substantial R&D investment precedes potential revenue generation. The emphasis on corporate governance, including independent directors and a clawback policy, aligns with evolving industry best practices and investor expectations for transparency and accountability in the biotech space.

Comparison to Industry Standards

• DiaMedica's executive compensation philosophy targets the 50th percentile of its peer group, which includes 18 clinical-stage biotechnology companies such as Acumen Pharmaceuticals, Inc., Anavex Life Sciences Corp., and Fulcrum Therapeutics, Inc. This approach is standard for companies aiming for competitive pay without leading the market.
• The company's three-year average equity burn rate of 5.3% (2023-2025) is within acceptable ranges for many growth-oriented biopharmaceutical companies, though it is on the higher side compared to some mature industry benchmarks, reflecting its clinical-stage status and reliance on equity incentives.
• The proposed overhang of 22.4% after the plan amendment, while higher than the pre-amendment 15.9%, is a metric closely watched by institutional investors. For clinical-stage biotechs, higher overhangs can be tolerated if justified by strong pipeline potential and a clear strategy for talent retention, but it still represents a notable dilution compared to industry averages for more established companies.
• The inclusion of robust corporate governance features, such as an independent Board Chairman, majority independent directors, and a clawback policy, aligns with best practices advocated by proxy advisory firms and institutional investors across the broader healthcare and technology sectors.

Management Changes

Corporate Governance

Related Party Transactions

• On June 25, 2024, the company issued and sold 4,720,000 common shares in a private placement at $2.50 per share. Trill AB and TomEnterprise AB, both beneficial owners of more than 5% of the company's common shares, each purchased 1,200,000 shares for $3,000,000.
• In connection with the June 2024 private placement, the company entered into a registration rights agreement with the investors. This agreement requires the company to keep a resale registration statement effective and includes a provision for liquidated damages of up to 10% of invested capital if the company fails to meet this obligation.

Stakeholder Impact

• **Shareholders**: Will be asked to vote on key governance matters, including director elections, auditor ratification, executive compensation, and a significant increase in the equity incentive plan, which could impact future dilution and talent retention. The strong TSR performance is beneficial, but increasing losses are a concern.
• **Employees**: The proposed amendment to the 2019 Omnibus Incentive Plan is designed to attract, motivate, and retain qualified personnel through equity-based compensation, directly benefiting employees eligible for awards.
• **Management**: Executive officers received base salary increases and significant short-term incentive payouts based on corporate and individual performance, and their long-term incentives are tied to stock options, aligning their interests with shareholder value.
• **Directors**: Non-employee directors receive a combination of cash retainers and long-term equity-based incentive compensation, with the option to receive deferred or restricted stock units in lieu of cash, ensuring their continued engagement and alignment with company performance.

Next Steps

• Shareholders will consider and vote on the four proposals at the Annual General Meeting on May 20, 2026.
• The Board of Directors will conduct a say-on-pay vote on an annual basis, with the next one scheduled for the 2027 Annual General Meeting.
• The next frequency of say-on-pay vote is expected to occur at the annual general meeting of shareholders to be held in 2030.
• The Audit Committee will reconsider its selection of Baker Tilly US, LLP if shareholders vote against their ratification.

Key Dates

Recommendation

The filing primarily addresses routine corporate governance matters and a proposed expansion of the equity incentive plan. While the plan expansion introduces potential dilution, it is a common and often necessary step for clinical-stage biopharmaceutical companies to attract and retain talent. The company's strong Total Shareholder Return (TSR) is a positive indicator, but this is balanced by continued and increasing net losses, which are expected for a company at this stage of development. There are no immediate catalysts or red flags that would warrant a 'buy' or 'sell' recommendation based solely on this proxy statement. A 'hold' recommendation allows investors to maintain their position while awaiting further clinical or financial updates.

Keywords

DiaMedica Therapeutics, SEC Filing, Proxy Statement, Annual General Meeting, Corporate Governance, Executive Compensation, Equity Incentive Plan, Stock Options, Shareholder Vote, Biopharmaceutical, Clinical Stage, Nasdaq, Risk Management, Director Election, Auditor Ratification, Say-on-Pay